京新藥業(002020.SZ)業績快報:2020年度淨利潤升25.57%至6.53億元
格隆匯 2 月 26日丨京新藥業(002020.SZ)披露2020年度業績快報,實現營業總收入32.60億元,同比下降10.60%;利潤總額7.53億元,同比增長24.79%;歸屬於上市公司股東的淨利潤6.53億元,同比增長25.57%;基本每股收益0.981元。
其中成品藥收入19.64億元、同比下降10.37%;原料藥收入8.01億元,同比下降14.63%;醫療器械收入4.50億元,同比下降5.13%。主要是受藥品集採影響,公司相關製劑產品及原料藥產品價格有明顯下降,但公司積極調整產品結構,推進核心產品規劃實施,重點產品銷售數量、市場份額明顯提升,業務結構更加合理;另外受新冠疫情影響, 醫療器械國際ODM業務部分訂單推延或取消,銷售收入同比略有下降,公司重點加大國內ODM業務、標準品業務拓展力度,2020年下半年起,已逐步恢復增長。
利潤增長主要是對外投資公允價值變動收益和理財收益大幅增長,2020年度非經常性損益約2.1億,同比增長約113%。歸屬於上市公司股東的扣除非經常性損益的淨利潤約4.4億,同比增長約5%,營業總收入下降同時實現了盈利增長,主要是公司通過體制和機制改革、研發創新、產品結構進一步調整優化,通過精益生產管理、提質增效、管理效能進一步提升,公司整體盈利水平實現了較好增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.